Mina Hosseini

Delighted to see this Symposium of @jlme-journal.bsky.social on Public Health, Markets, and Law is now out.

Many thanks to @minacompetition.bsky.social and Imelda Maher!

My article considers #hospitals #stateaid and #SGEI

www.cambridge.org/core/journal...

The September issue of the Journal of Law, Medicine & Ethics is now online.

This issue features the open-access symposium Public Health, Markets, and Law, guest edited by @minacompetition.bsky.social and Imelda Maher, with incisive, in-depth articles.

Read now: www.cambridge.org/core/journal...

Symposium Articles EU’s Extraterritorial Obligations for Global Medicine Access Under the Convention on the Rights of Persons with Disability (CPRD) Katrina Perehudoff1,2,3,4,5 1University of Amsterdam Amsterdam Law School, Law for Health and Life, Netherlands; 2Amsterdam Institute for Global Health and Development, Netherlands; 3Amsterdam Centre for European Studies, University of Amsterdam; 4Amsterdam Centre for European Law and Governance, University of Amsterdam and 5Medicines Law & Policy, Amsterdam, the Netherlands Abstract Equitable access to medicines is vital for people with disabilities to receive effective, affordable, and quality treatment, helping preserve functionality, prevent further disability, and promote social and economic inclusion. This paper explores the specific medicine needs of people with disabilities in low- and middle-income countries (LMICs), focusing on the European Union’s (EU) extraterritorial legal obligations under the Convention on the Rights of Persons with Disabilities (CRPD). As the first regional international organization to accede to a UN human rights treaty, the EU offers a unique case for examining how international legal commitments extend beyond its borders. The paper outlines a legal framework based on the CRPD to assess the EU’s responsibilities for ensuring access to medicines globally. This framework is applied to two case studies: the EU’s internal joint COVID-19 vaccine procurement strategy and its external BioNTainer initiative for vaccine production in Africa under Team Europe. The analysis finds that the EU falls short of its CRPD obligations, particularly in areas of technology transfer and intellectual property sharing, which are essential for equitable global vaccine access. The paper concludes that the EU’s current actions do not fulfill its human rights commitments to people with disabilities in LMICs. Keywords: access to medicines; disability rights; pharmaceuticals; European Union; intellectual property

New open-access on FirstView: "EU’s Extraterritorial Obligations for Global Medicine Access Under the Convention on the Rights of Persons with Disability (CPRD)" by
‪@katperehudoff.bsky.social‬ from special issue "Public Health, Markets, and Law." #DisabilityRights
www.cambridge.org/core/journal...

Day 2 #UACES2025 saw our 3rd panel on data exclusivity vouchers, global health, wellness devices, and solidarity in European healthcare!

Many thanks to Paula Dornbusch, Ian Manners, Federica Casarosa and Mary Guy

Our final panel at #UACES2025 considered the balance between health and other EU policies - ethics, trade, alcohol brand marketing, and AI.

Many thanks to Juan Collado Perez Llantada, @merikoivusalo.bsky.social, Jaydon Souter, and Phil Ryan!

We’re having a great time at #UACES2025!

Day 1 included presentations on complexity, Covid-19, competition law, cross-border telemedicine and forced migrants’ access to health and healthcare

Many thanks @eleanorbrooks.bsky.social @minacompetition.bsky.social @mechthildroos.bsky.social & others!

Grand #UACES2025 walking tour of Liverpool this afternoon - taking in reconciling the city’s slave trade history, football, and a certain boyband…

Thanks Lauren for the group photo!

With @PramitiParwani & @katperehudoff.bsky.social, we explored EU pharma regulators’ role in access to medicines in low-income countries. Trust remains one-way, reinforcing dependencies; building regional regulatory capacity is key for global health 💫

Symposium Articles Trust Beyond Borders: European External Regulatory Influence on Access to Medicines Pramiti Parwani1,2,3 , Katrina Perehudoff1,2,3 and Anniek de Ruijter1,2 1University of Amsterdam, Amsterdam Law School, Law for Health and Life, Netherlands; 2Amsterdam Institute for Global Health and Development, Netherlands and 3Amsterdam Centre for European Law and Governance, University of Amsterdam, Netherlands Abstract European institutions are widely recognized as wielding regulatory power in a globalized market, exporting its standards across borders and between sectors. This paper asks what institutional dynamics catalyze European external regulatory impact on pharmaceutical governance in low- and middle-income countries (LMICs). The research focuses on two European regulatory bodies, the European Medicines Agency (EMA) and the European Patent Office (EPO), and explores the dynamics of their technocratic outreach beyond European borders. We find that trust is a key underlying institutional dynamic facilitating some forms of European external relations. The agencies extend their influence through technical assistance, collaboration, and work-sharing with LMIC regulators, fostering a one-sided relationship of“technocratic trust.” This trust, reinforced by international regulatory frameworks that position the EMA and EPO as“trustworthy” regulators, enables these agencies to expand their regulatory influence beyond Europe. By critically examining the impact of this trust-building on LMICs’ regulatory autonomy, this research contributes to the broader discourse on European regulatory power in global health governance and highlights potential implications for pharmaceutical markets and access in LMICs. Keywords: European Regulatory Bodies; Pharmaceuticals Access; European Medicines Agency (EMA); European Patent Office (EPO); Trust

New open access on FirstView: "Trust Beyond Borders: European External Regulatory Influence on Access to Medicines" by Pramiti Parwani, ‪@katperehudoff.bsky.social‬, and @deruijter.bsky.social from the upcoming fall special issue "Public Health, Markets, and Law."
www.cambridge.org/core/journal...

Symposium Articles Abuse of Dominant Position, Effective Judicial Protection and Abuse of Procedure Carmen de Vivero de Porras and Enrique Sanjuán y Muñoz School of Law, University of Malaga, Spain Abstract On October 21, 2022, the Spanish Competition Agency (CNMC) sanctioned the North American pharmaceutical company Merck Sharp & Dohme for abuse of a dominant position. The practice for which it was finally sanctioned consisted of the adoption of a strategy aimed at delaying and making it difficult for another company to enter the Spanish medicines market in order to protect sales for a product marketed exclusively by that company and for which had a patent. This paper analyzes this resolution in an attempt to delimit the difference between the legitimate exercise of the right to effective judicial protection and its abuse. Keywords: competition; strategy; medicines market; dominant position; market

New open-access on FirstView: "Abuse of Dominant Position, Effective Judicial Protection and Abuse of Procedure" by Carmen de Vivero de Porras and Enrique Sanjuán y Muñoz analyzes the attempt to keep a generic alternative to NuvaRing out of the market.
www.cambridge.org/core/journal...

Fascinated by #ElizabethHolmes of #Theranos and her wild journey from digital health entrepreneur heroine to villaine and #Girlboss? Asking yourself in whose interest it all happened? So were we!

@keanbirch.bsky.social @provokedeconomy.bsky.social @allartmarkets.bsky.social you might like this one

Proud to share this new publication on #hospitals #stateaid and #SGEI in the excellent Symposium on “Public Health, Markets, and Law” with @jlme-journal.bsky.social
edited by Dr Mina Hosseini and Imelda Maher.

Some key findings follow!

www.cambridge.org/core/journal...

Symposium Articles Competition Law and Ethics of Innovation as Catalysts for Fairness: Reimagining the EU’s COVID-19 Vaccine Strategy Mina Hosseini Sutherland School of Law, University College Dublin, Ireland Abstract The“EU Vaccines Strategy” launched by the European Commission in June 2020 aimed to ensure vaccine safety, equitable access, affordability, swift distribution, and global solidarity for COVID-19 vaccines. This study critiques the Commission’s centralized procurement approach, focusing on Advance Purchase Agreements (APAs) through a literature review, policy analysis, and a case study of the EU-AstraZeneca’s APA. It identifies critical challenges, including transparency deficits, accountability gaps, and anticompetitive practices by vaccine producers that undermine equitable access. Drawing on these insights, the study proposes the FACER Framework— Fairness, Accountability, Competition Law, Ethics of Innovation, and Resilience— a novel model integrating the Treaty on the European Union (TEU) and the Treaty on the Functioning of the European Union (TFEU) oversight with ethical principles. By embedding legal and moral accountability, FACER offers EU policymakers a robust tool to enhance vaccine strategy and equity in future health crises. Keywords: Pharmaceutical Procurement; EU Vaccines Strategy; Advance Purchase Agreements; Competition Law; Ethics of Innovation

New open access article on FirstView: "Competition Law and Ethics of Innovation as Catalysts for Fairness: Reimagining the EU’s COVID-19 Vaccine Strategy" by @minacompetition.bsky.social, part of the upcoming symposium "Public Health, Markets and Law."
www.cambridge.org/core/journal...

Thank you Mary 🙏

Great to see this new article by
@minacompetition.bsky.social in @jlme-journal.bsky.social!

www.cambridge.org/core/journal...

Delighted to see the first paper from our Symposium “Public Health, Markets and Law” co-edited with Professor Imelda Maher now published in @jlme-journal.bsky.social @ucdschooloflaw.bsky.social @ucddublin.bsky.social

Future-AI Consortium Tackle Trustworthy AI in Healthcare - LHL We are excited to announce that Mahsa Shabani from the Law Centre for Health and Life is part of the pioneering Future-AI consortium.

Mahsa Shabani from Law for Health and Life contributed to Future-AI’s global guidelines for trustworthy AI in healthcare—now published in The BMJ! A major step toward safer, ethical AI.

🔗 Read more: https://bit.ly/4i4RN9d

#CoerciveInJustice is now online! 🛜 Check out our new website: www.coerciveinjustice.com to learn about the research project, meet the team, and catch up on all the latest news and events.

‼️ CALL FOR PAPERS - ECRs IN IRELAND/UK ‼️

Save an #ECR, spread with your network 😉

▶️"'Law and...' Reflections on interdisciplinarity and the law from ECAs in 🇮🇪 & 🇬🇧"

📆Dublin, Jun 12th 2025

⏰Submissions Deadline: Apr 1st 2025

Thinking about applying for a Marie Curie fellowship this year?

Join Cathryn Costello, @liliantsourdi.bsky.social, @minacompetition.bsky.social, Violeta Moreno-Lax and me next Tuesday at 12:00 CET.

Delighted that our article with Imelda Maher has been nominated for Concurrences 2025 Antitrust Writing Awards. Vote for us here: awards.concurrences.com/en/awards/20...

Hello BlueSky!

We’re EUHealthGov- here for EU health law and policy, working with academics, policymakers, practitioners…

Check out our website for information about our events

www.euhealthgov.org

Two wonderful global health scholars have made their global health books free to download

Bravo and thanks @seyeabimbola.bsky.social and
@thewrittenro.bsky.social

The Foreign Gaze:
www.editions.ird.fr/open_access_...

Rethinking Global Health:
taylorfrancis.com/books/oa-mon...

Of Disparagement and Other Demons: Trends in EU Competition Law Enforcement in the Pharmaceutical Sector - Constitutional Discourse Disparagement practices (spreading misleading information to undermine competitors’ products) as an anti-competitive practice in the pharmaceutical sector is not a new topic in EU competition law. How...

Published today in Constitutional Discourse My New blog post: "Of Disparagement & Other Demons: Trends in EU Competition Law Enforcement in the Pharmaceutical Sector "

constitutionaldiscourse.com/of-disparage...

Part of my #MSCA project #COMPHACRISIS #EUAntitrust #Pharma #Health #Disparagement

I am happy that our chapter with Imelda Maher, 'Competition Law Institutions and Future Challenges,' has just been published as part of the landmark collection, Why Competition, by Concurrences. @ucdschooloflaw.bsky.social

The Call for Papers for the UACES 55th Annual Conference 2025 at Liverpool John Moores University is officially open!

Join us from 31 August to 3 September 2025, to explore Europe’s resilience in a changing world.

Submit your paper by 26 January 2025 👉 www.conftool.org/uaces2025/

#CfP #UACES2025

The report from the #COMPHACRISIS #MSCA Finsl Workshop on 'Healthcare at the Crossroads: Regulation, Innovation, and Market Dynamics' (Sep 13, 2024, UCD) is now available! Explore key insights on EU healthcare competition and policy: zenodo.org/records/1380...